PL1909755T3 - Nanotechnologia cyklodekstryn do dostarczania leku do oczu - Google Patents
Nanotechnologia cyklodekstryn do dostarczania leku do oczuInfo
- Publication number
- PL1909755T3 PL1909755T3 PL06808951T PL06808951T PL1909755T3 PL 1909755 T3 PL1909755 T3 PL 1909755T3 PL 06808951 T PL06808951 T PL 06808951T PL 06808951 T PL06808951 T PL 06808951T PL 1909755 T3 PL1909755 T3 PL 1909755T3
- Authority
- PL
- Poland
- Prior art keywords
- nanotechnology
- cyclodextrins
- eyes
- drug delivery
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70162105P | 2005-07-22 | 2005-07-22 | |
| US79556306P | 2006-04-28 | 2006-04-28 | |
| PCT/IB2006/002769 WO2007012974A2 (en) | 2005-07-22 | 2006-07-21 | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| EP06808951.5A EP1909755B1 (en) | 2005-07-22 | 2006-07-21 | Cyclodextrin nanotechnology for ophthalmic drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1909755T3 true PL1909755T3 (pl) | 2018-10-31 |
Family
ID=37564167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06808951T PL1909755T3 (pl) | 2005-07-22 | 2006-07-21 | Nanotechnologia cyklodekstryn do dostarczania leku do oczu |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US7893040B2 (pl) |
| EP (1) | EP1909755B1 (pl) |
| ES (1) | ES2675043T3 (pl) |
| PL (1) | PL1909755T3 (pl) |
| WO (1) | WO2007012974A2 (pl) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020298A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| EP1806129A1 (en) * | 2004-10-01 | 2007-07-11 | Eisai R&D Management Co., Ltd. | Composition containing fine particles and process for producing the same |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US20070212397A1 (en) * | 2005-09-15 | 2007-09-13 | Roth Daniel B | Pharmaceutical delivery device and method for providing ocular treatment |
| KR101482483B1 (ko) | 2006-04-07 | 2015-01-15 | 에르피오 세러퓨틱스 인코포레이티드 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US8435544B2 (en) | 2007-10-08 | 2013-05-07 | Lux Biosciences, Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
| PL2234614T3 (pl) | 2007-12-21 | 2013-03-29 | Aop Orphan Pharmaceuticals Ag | Kompozycja farmaceutyczna do pozajelitowego podawania ultrakrótko działającego antagonisty receptora beta-adrenergicznego |
| PT2262506E (pt) * | 2008-03-11 | 2014-06-24 | Alcon Res Ltd | Suspensões de acetonido de triamcinolona de baixa viscosidade altamente floculadas para injeção intravítrea |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| TWI580441B (zh) * | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | 穩定的藥學次微米懸浮液及其形成方法 |
| US20100105643A1 (en) * | 2008-10-27 | 2010-04-29 | Soll David B | Ophthalmic composition |
| US20110125090A1 (en) * | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| CA3045436C (en) | 2009-01-29 | 2025-10-07 | Forsight Vision4, Inc. | ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT |
| WO2010144194A1 (en) * | 2009-06-09 | 2010-12-16 | Lux Biosciences, Inc. | Topical drug delivery systems for ophthalmic use |
| ES2726946T3 (es) | 2009-07-06 | 2019-10-10 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas |
| ES2351756B1 (es) | 2009-07-28 | 2011-10-05 | Universidad Del Pais Vasco | Nanopartículas lipídicas para terapia génica. |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| WO2011113904A1 (en) * | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| KR20130102037A (ko) * | 2010-07-22 | 2013-09-16 | 메르츠 파마 게엠베하 운트 코. 카가아 | 트립토판 유도체를 함유하는 약학 조성물 |
| CN103209664A (zh) | 2010-08-05 | 2013-07-17 | 弗赛特影像4股份有限公司 | 可植入的治疗装置 |
| CN103153316B (zh) | 2010-08-05 | 2015-08-19 | 弗赛特影像4股份有限公司 | 组合药物递送方法和设备 |
| WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
| US20130281420A1 (en) * | 2010-08-17 | 2013-10-24 | Ohr Pharmaceutical, Inc. | Ophthalmic Formulations of Squalamine |
| AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| ES2385080B1 (es) * | 2010-12-21 | 2013-05-10 | Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea | Nanopartículas lipídicas para el tratamiento de enfermedades oculares. |
| WO2012114342A1 (en) | 2011-02-23 | 2012-08-30 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
| EP2726016B1 (en) | 2011-06-28 | 2023-07-19 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
| SI2755600T1 (sl) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Naprava za izmenjavo tekočine |
| CA2850830A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| RU2672596C2 (ru) * | 2012-01-23 | 2018-11-16 | Аллерган, Инк. | Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| EP4083075A1 (en) | 2012-02-15 | 2022-11-02 | CyDex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| HK1208162A1 (en) | 2012-05-03 | 2016-02-26 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| WO2014127015A1 (en) * | 2013-02-12 | 2014-08-21 | Ys Pharm Tech | Epinephrine formulations for medicinal products |
| SG11201506372RA (en) * | 2013-03-13 | 2015-09-29 | Seattle Genetics Inc | Cyclodextrin and antibody-drug conjugate formulations |
| KR102433489B1 (ko) * | 2013-03-14 | 2022-08-17 | 팬옵티카, 인크. | 눈의 후안부로의 약물 전달을 위한 안구용 제제 |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| GB2516561B (en) | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| AU2014241163B2 (en) | 2013-03-28 | 2018-09-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| FR3006315B1 (fr) * | 2013-05-31 | 2015-10-02 | Centre Nat Rech Scient | Microparticules et nanoparticules auto-associatives composees de proteines |
| US20160151410A1 (en) * | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| US9511341B2 (en) | 2013-08-30 | 2016-12-06 | Sunny Pharmtech Inc. | Method for preparing acetazolamide sodium powder |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| WO2015175954A1 (en) * | 2014-05-16 | 2015-11-19 | Scifluor Life Sciences, Inc. | Alpha v integrin antagonist compositions |
| RU2695563C2 (ru) | 2014-07-15 | 2019-07-24 | Форсайт Вижн4, Инк. | Способ и устройство для доставки глазного имплантата |
| MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| JP7037360B2 (ja) | 2014-11-10 | 2022-03-16 | フォーサイト・ビジョン フォー・インコーポレーテッド | 拡張可能な薬物送達デバイス |
| US9694109B1 (en) * | 2015-01-06 | 2017-07-04 | Brahm Holdings, Llc | Nanoparticle-containing placental constructs and methods of use |
| KR20180028992A (ko) * | 2015-05-29 | 2018-03-19 | 오쿨리스 이에이치에프. | 시클로스포린 a/시클로덱스트린 나노입자의 형성 |
| ES2971096T3 (es) | 2015-06-06 | 2024-06-03 | Cloudbreak Therapeutics Llc | Composiciones y métodos para tratar el terigio |
| US10555952B2 (en) | 2015-06-19 | 2020-02-11 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| US20200297734A1 (en) | 2015-06-19 | 2020-09-24 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| ES2604816B1 (es) * | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
| MY194736A (en) | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| KR20180084104A (ko) | 2015-11-20 | 2018-07-24 | 포사이트 비젼4, 인크. | 연장 방출 약물 전달 장치를 위한 다공성 구조물 |
| BR112018070383A2 (pt) | 2016-04-05 | 2019-02-05 | Forsight Vision4 Inc | dispositivos para aplicação de fármaco oculares implantáveis |
| CA3026118A1 (en) | 2016-06-02 | 2017-12-07 | Cloudbreak Therapeutics, Llc | Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization |
| GB2556082A (en) * | 2016-11-18 | 2018-05-23 | Warneford Healthcare Ltd | Ophthalmic composition |
| HUE057221T2 (hu) * | 2016-11-29 | 2022-04-28 | Oculis SA | Szilárd ciklodextrin komplexek készítményei szemészetileg aktív gyógyászati hatóanyag adagolásához |
| US20180177744A1 (en) * | 2016-12-22 | 2018-06-28 | Gary Jay | Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine |
| EP3573664A4 (en) * | 2017-01-27 | 2020-11-11 | Innovative Nano & Micro Technologies Pvt Ltd (INM Technologies) | ACETAZOLAMIDE CONTAINING OPHTHALMIC SOLUTION |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| JP2020535217A (ja) * | 2017-09-01 | 2020-12-03 | マリー アンド プール エンタープライゼズ,リミテッド | 眼病態を治療するための方法および組成物 |
| CN115607358A (zh) | 2017-11-21 | 2023-01-17 | 弗赛特影像4股份有限公司 | 用于可扩展端口递送系统的流体交换装置及使用方法 |
| US20240016954A1 (en) * | 2017-12-26 | 2024-01-18 | Industrial Technology Research Institute | Composition for improving the solubility of poorly soluble substances, complex formulation and liquid formulation of an active ingredient |
| ES2914305T3 (es) * | 2017-12-26 | 2022-06-09 | Ind Tech Res Inst | Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma |
| WO2019231858A1 (en) * | 2018-06-01 | 2019-12-05 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
| US12343163B2 (en) | 2018-08-09 | 2025-07-01 | Michael Feeney | Imaging system and method for enhanced visualization of near surface vascular structures |
| WO2020223209A1 (en) | 2019-04-29 | 2020-11-05 | Aerpio Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| US10952981B2 (en) * | 2019-05-27 | 2021-03-23 | Slayback Pharma Llc | Liquid pharmaceutical compositions of baclofen for oral administration |
| SI3993807T1 (sl) | 2019-07-01 | 2026-04-30 | Oculis Operations Sarl | Postopek za stabiliziranje ph vodnega sestavka, ki obsega zdravilo |
| EP4121417A4 (en) * | 2020-05-01 | 2023-08-09 | University Of Southern California | CYCLODEXTRIN-BASED ANTIMICROBIAL THERAPY |
| HU231668B1 (hu) * | 2021-12-28 | 2025-06-28 | Semmelweis Egyetem 60% | Szemcsepp készítmény |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| CN114558046B (zh) * | 2022-01-30 | 2023-06-23 | 潍坊医学院附属医院 | 一种改善稳定性的眼科制剂及其制备方法 |
| CN118647364A (zh) * | 2022-02-02 | 2024-09-13 | 奥库里斯经营管理有限责任公司 | 多剂量眼用组合物 |
| US20250288548A1 (en) * | 2022-05-02 | 2025-09-18 | The Regents Of The University Of California | Intranasal baclofen |
| EP4356929A1 (en) | 2022-10-19 | 2024-04-24 | Universität Rostock | Antifibrotic formulation for ophthalmic treatment |
| WO2024091659A1 (en) * | 2022-10-28 | 2024-05-02 | Aldeyra Therapeutics, Inc. | Modified cyclodextrins and ophthalmic uses thereof |
| WO2024239072A1 (en) * | 2023-05-25 | 2024-11-28 | The University Of Melbourne | Iontophoresis pharmaceutical delivery system |
| WO2025082585A1 (en) | 2023-10-16 | 2025-04-24 | Oculis Operations Sàrl | Method of treating diabetic macular edema |
| TW202519198A (zh) | 2023-10-16 | 2025-05-16 | 瑞士商歐可麗營運有限公司 | 治療糖尿病黃斑水腫的方法 |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
| WO2026094048A1 (en) | 2024-10-30 | 2026-05-07 | Able Tx Ltd. | Drug delivery to the posterior eye segment |
| GR1011143B (el) * | 2025-04-11 | 2026-03-02 | Ιουλια Τσετη | Οφθαλμικο διαλυμα προσταγλανδινης χωρις συντηρητικα |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| EP0709099A3 (en) | 1994-09-28 | 1996-07-24 | Senju Pharma Co | Aqueous suspension for nasal administration containing cyclodextrin |
| ES2584183T3 (es) | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
| DE602004023516D1 (de) * | 2003-08-07 | 2009-11-19 | Allergan Inc | Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
-
2006
- 2006-07-20 US US11/489,466 patent/US7893040B2/en active Active
- 2006-07-21 EP EP06808951.5A patent/EP1909755B1/en active Active
- 2006-07-21 ES ES06808951.5T patent/ES2675043T3/es active Active
- 2006-07-21 PL PL06808951T patent/PL1909755T3/pl unknown
- 2006-07-21 WO PCT/IB2006/002769 patent/WO2007012974A2/en not_active Ceased
-
2011
- 2011-01-27 US US13/014,964 patent/US20120028944A1/en not_active Abandoned
-
2013
- 2013-02-04 US US13/758,955 patent/US8633172B2/en active Active
- 2013-12-13 US US14/106,265 patent/US8999953B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US7893040B2 (en) | 2011-02-22 |
| EP1909755A2 (en) | 2008-04-16 |
| ES2675043T3 (es) | 2018-07-06 |
| US8999953B2 (en) | 2015-04-07 |
| EP1909755B1 (en) | 2018-04-25 |
| US20070020336A1 (en) | 2007-01-25 |
| WO2007012974A2 (en) | 2007-02-01 |
| US20140186443A1 (en) | 2014-07-03 |
| WO2007012974A3 (en) | 2007-07-12 |
| US20120028944A1 (en) | 2012-02-02 |
| US8633172B2 (en) | 2014-01-21 |
| US20130142791A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2018030I1 (el) | Φαρμακοτεχνικη μορφη 514 | |
| DE112006001565A5 (de) | Nanopartikel-Wirkstoff-Konjugate | |
| HUS1600048I1 (hu) | Készítmény Fabry-kór kezelésére | |
| BRPI0810928A2 (pt) | "composição farmacêutica" | |
| PL2136865T3 (pl) | Podawanie donosowe | |
| BRPI1012004A2 (pt) | "forma farmacêutica" | |
| BRPI0913379A2 (pt) | formulações farmacêuticas sólidas compreendendo bibw 2992 | |
| EP2132133A4 (en) | RELEASE OF PARTICULATE ACTIVE SUBSTANCES | |
| BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| BRPI1014027A2 (pt) | suspensão de fármaco de nanopartícula estável. | |
| DK2151438T3 (da) | Lægemiddel indeholdende PPAR-Deltaagonist | |
| BRPI0714539A2 (pt) | "formas farmacêuticas" | |
| PL2504005T3 (pl) | Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby | |
| EP2124556A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| HRP20170959T1 (hr) | Farmaceutska suspenzija | |
| EP2340271A4 (en) | CONJUGATES OF POLYMER-BIOACTIVE SUBSTANCES | |
| EP2193795A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST | |
| EP2438217A4 (en) | ELECTRICALLY STORED GOLDNANO STRUCTURES | |
| DK1957073T3 (da) | Lægemiddel | |
| SI1942967T1 (sl) | Postopek za odmerjanje zdravil | |
| BRPI0821026A2 (pt) | Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos | |
| DK2271321T3 (da) | Farmaceutisk sammensætning 271 | |
| IT1392547B1 (it) | Dispositivo per l'infusione di farmaci | |
| EP2258697A4 (en) | HYDROXYCHINOXALINCARBOXAMIDDERIVAT |